Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MESAMI2: Intramyocardial MSCs in Chronic Ischemic Cardiomyopathy
NCT02462330Phase 2Completed
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Feb 2016
- Primary completion
- Dec 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mesenchymal stem cells in ischemic cardiomyopathy (ICM) (2 arms), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Change in VO2max at 3 months. Started Feb 2016; status: completed.
02
Drugs
mesenchymal stem cells
03
Conditions
ischemic cardiomyopathy (ICM)
Beyond the preview
Go deeper on NCT02462330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02462330.